SCHEMBL3560972

SCHEMBL3560972

FC(F)(F)c1ccc(-c2cc(C(F)(F)F)cc(-c3ccnc(I)c3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 3/20 0.46
KIF11 P52732 1/20 0.44
S1PR1 P21453 2/20 0.41
S1PR3 Q99500 1/20 0.40
RAD51 Q06609 1/20 0.39
TGFBR1 P36897 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
MAPKAPK2 P49137 1/20 0.38
LTA4H P09960 1/20 0.38
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
HDAC1 Q13547 1/20 0.37
CCNT1 O60563 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560497 0.82 S1PR1 (0.59) TOP1KIF11S1PR1S1PR3TGFBR1
SCHEMBL3568189 0.80 TOP1 (0.45) TOP1KIF11RAD51KDM4EMEN1
SCHEMBL4659271 0.77 RAD51 (0.40) TOP1KIF11RAD51KDM4EMEN1
SCHEMBL3564372 0.75 TGFBR1 (0.45) TOP1KIF11TGFBR1MAPKAPK2LTA4H
SCHEMBL3556298 0.73 TOP1 (0.39) TOP1KIF11RAD51KDM4EABL1
SCHEMBL27764812 0.73 KIF11 (0.52) TOP1KIF11S1PR1TGFBR1ABL1
SCHEMBL3559671 0.72 S1PR1 (0.55) TOP1KIF11S1PR1S1PR3RAD51
SCHEMBL15534703 0.72 KIF11 (0.47) TOP1KIF11S1PR1S1PR3KDM4E
SCHEMBL29473456 0.71 KDM4E (0.56) TOP1KDM4ENPSR1L3MBTL1
SCHEMBL3557747 0.71 LRRK2 (0.47) TOP1KIF11TGFBR1ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001849-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-26 EP disclosed
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 TOP1 4341/4885KIF11 3845/4885S1PR1 1042/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 TOP1 4434/4885KIF11 3339/4885S1PR1 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.